The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
IL-1 Family Members in Cancer; Two Sides to Every Story
Open accessAbstract
The IL-1 family of cytokines currently comprises of seven ligands with pro-inflammatory activity (IL-1α and IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ) as well as two ligands with anti-inflammatory activity (IL-37, IL-38). These cytokines are known to play a key role in modulating both the innate and adaptive immunes response, with dysregulation linked to a variety of autoimmune and inflammatory diseases. Given the increasing appreciation of the link between inflammation and cancer, the role of several members of this family in the pathogenesis of cancer has been extensively investigated. In this review, we highlight both the pro- and anti-tumorigenic effects identified for almost all members of this family, and explore potential underlying mechanisms accounting for these divergent effects. Such dual functions need to be carefully assessed when developing therapeutic intervention strategies targeting these cytokines in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“Tumor cells themselves can also directly induce an immunosuppressive microenvironment through recruitment and activation of specific immune cell subtypes such as myeloid derived suppressor cells (MDSC), M2 macrophages and T regulatory cells, further promoting tumorigenesis (2, 4, 5).”
Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.09.015 · Cited by 3,710
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945
Imai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
Weber, A., Wasiliew, P., & Kracht, M. (2010) · Science Signaling · doi:10.1126/scisignal.3105cm1 · Cited by 962 · cited 1×
“IL-1α and IL-1β bind the same receptor, the type 1 IL-1 receptor (IL-1R), recruiting both the IL-1R accessory protein and the adaptor protein MyD88 to the receptor complex, resulting in activation of the downstream signaling cascade and ultimately in the activation of a myriad of immune and inflammatory genes (7).”
BackgroundRomee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
IL-37 is a fundamental inhibitor of innate immunity
Nold, M. F., Nold-Petry, C. A., Zepp, J. A., Palmer, B. E., Bufler, P., & Dinarello, C. A. (2010) · Nature Immunology · doi:10.1038/ni.1944 · Cited by 849
Allen, I. C., TeKippe, E. M., Woodford, R.-M. T., Uronis, J. M., Holl, E. K., Rogers, A. B., Herfarth, H. H., Jobin, C., & Ting, J. P.-Y. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100050 · Cited by 826
Shields, M., & Lonergan Institute at Boston College (2001) · Method · doi:10.5840/method20011916 · Cited by 748
Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M. A., Vallejo, C., Martos, J. A., & Moreno, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970615)79:12<2320::aid-cncr5>3.0.co;2-p · Cited by 716
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation
Hayakawa, H., Hayakawa, M., Kume, A., & Tominaga, S.-I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704916200 · Cited by 546
Villegas, F. R., Coca, S., Villarrubia, V. G., Jiménez, R., Chillón, M. J., Jareño, J., Zuil, M., & Callol, L. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00292-6 · Cited by 467
Kaplanov, I., Carmi, Y., Kornetsky, R., Shemesh, A., Shurin, G. V., Shurin, M. R., Dinarello, C. A., Voronov, E., & Apte, R. N. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812266115 · Cited by 445
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
van de Veerdonk, F. L., Stoeckman, A. K., Wu, G., Boeckermann, A. N., Azam, T., Netea, M. G., Joosten, L. A. B., van der Meer, J. W. M., Hao, R., Kalabokis, V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121534109 · Cited by 380
Sautès-Fridman, C., Lawand, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Dieu-Nosjean, M.-C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00407 · Cited by 379
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy
Mantovani, A., Barajon, I., & Garlanda, C. (2018) · Immunological Reviews · doi:10.1111/imr.12614 · Cited by 376
Dinarello, C. A. (1999) · Methods · doi:10.1006/meth.1999.0837 · Cited by 369
IL-37: a new anti-inflammatory cytokine of the IL-1 family
Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., Mangelberger, D., Oostingh, G. J., Pfaller, T., Pixner, C., Posselt, G., et al. (2011) · European Cytokine Network · doi:10.1684/ecn.2011.0288 · Cited by 357
Jovanovic, I. P., Pejnovic, N. N., Radosavljevic, G. D., Pantic, J. M., Milovanovic, M. Z., Arsenijevic, N. N., & Lukic, M. L. (2014) · International Journal of Cancer · doi:10.1002/ijc.28481 · Cited by 328
IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation
Li, Y., Wang, L., Pappan, L., Galliher-Beckley, A., & Shi, J. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-87 · Cited by 319
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Haabeth, O. A. W., Lorvik, K. B., Hammarström, C., Donaldson, I. M., Haraldsen, G., Bogen, B., & Corthay, A. (2011) · Nature Communications · doi:10.1038/ncomms1239 · Cited by 318
Targeting inflammasome/IL-1 pathways for cancer immunotherapy
Guo, B., Fu, S., Zhang, J., Liu, B., & Li, Z. (2016) · Scientific Reports · doi:10.1038/srep36107 · Cited by 302
Endotoxin-induced serum factor that stimulates gamma interferon production
Nakamura, K., Okamura, H., Wada, M., Nagata, K., & Tamura, T. (1989) · Infection and Immunity · doi:10.1128/iai.57.2.590-595.1989 · Cited by 299
Suppression of inflammation and acquired immunity by IL‐37
Cavalli, G., & Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12605 · Cited by 291
Nakao, S., Kuwano, T., Tsutsumi-Miyahara, C., Ueda, S.-I., Kimura, Y. N., Hamano, S., Sonoda, K.-H., Saijo, Y., Nukiwa, T., Strieter, R. M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23298 · Cited by 286
Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., Huszar, M., Iwakura, Y., Segal, S., Dinarello, C. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2956 · Cited by 285
S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β
Weichand, B., Popp, R., Dziumbla, S., Mora, J., Strack, E., Elwakeel, E., Frank, A.-C., Scholich, K., Pierre, S., Syed, S. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160392 · Cited by 267
Saijo, Y., Tanaka, M., Miki, M., Usui, K., Suzuki, T., Maemondo, M., Hong, X., Tazawa, R., Kikuchi, T., Matsushima, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.469 · Cited by 249
Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S., Hayman, S. R., Russell, S. J., Buadi, F. K., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.114 · Cited by 246
Gao, X., Wang, X., Yang, Q., Zhao, X., Wen, W., Li, G., Lu, J., Qin, W., Qi, Y., Xie, F., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401344 · Cited by 242
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer
Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W. H., Sautès-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.22009 · Cited by 235
Nakamura, K., Kassem, S., Cleynen, A., Chrétien, M.-L., Guillerey, C., Putz, E. M., Bald, T., Förster, I., Vuckovic, S., Hill, G. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.007 · Cited by 233
Osaki, T., Péron, J., Cai, Q., Okamura, H., Robbins, P. D., Kurimoto, M., Lotze, M. T., & Tahara, H. (1998) · PubMed · Cited by 231
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis
Marshall, E. A., Ng, K. W., Kung, S. H. Y., Conway, E. M., Martinez, V. D., Halvorsen, E. C., Rowbotham, D. A., Vucic, E. A., Plumb, A. W., Becker-Santos, D. D., et al. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0551-1 · Cited by 231
Li, S., Neff, C. P., Barber, K., Hong, J., Luo, Y., Azam, T., Palmer, B. E., Fujita, M., Garlanda, C., Mantovani, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424626112 · Cited by 230
Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions
Gabay, C., & Towne, J. E. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri1014-495r · Cited by 228
Cloning and Characterization of IL-1HY2, a Novel Interleukin-1 Family Member
Lin, H., Ho, A. S., Haley-Vicente, D., Zhang, J., Bernal-Fussell, J., Pace, A. M., Hansen, D., Schweighofer, K., Mize, N. K., & Ford, J. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010095200 · Cited by 218
Apte, R. N., Krelin, Y., Song, X., Dotan, S., Recih, E., Elkabets, M., Carmi, Y., Dvorkin, T., White, R. M., Gayvoronsky, L., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.010 · Cited by 211
The Role of IL-1β in the Early Tumor Cell–Induced Angiogenic Response
Carmi, Y., Dotan, S., Rider, P., Kaplanov, I., White, M. R., Baron, R., Abutbul, S., Huszar, M., Dinarello, C. A., Apte, R. N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202769 · Cited by 209
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β
Shchors, K., Shchors, E., Rostker, F., Lawlor, E. R., Brown-Swigart, L., & Evan, G. I. (2006) · Genes & Development · doi:10.1101/gad.1455706 · Cited by 200
Hong, D. S., Hui, D., Bruera, E., Janku, F., Naing, A., Falchook, G. S., Piha-Paul, S., Wheler, J. J., Fu, S., Tsimberidou, A. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70155-x · Cited by 199
Lucarini, V., Ziccheddu, G., Macchia, I., La Sorsa, V., Peschiaroli, F., Buccione, C., Sistigu, A., Sanchez, M., Andreone, S., D'Urso, M. T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1317420 · Cited by 199
Regulation and function of interleukin‐36 cytokines
Bassoy, E. Y., Towne, J. E., & Gabay, C. (2018) · Immunological Reviews · doi:10.1111/imr.12610 · Cited by 197
IFN-γ-Inducing Factor/IL-18 Administration Mediates IFN-γ- and IL-12-Independent Antitumor Effects
Osaki, T., Péron, J.-M., Cai, Q., Okamura, H., Robbins, P. D., Kurimoto, M., Lotze, M. T., & Tahara, H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.4.1742 · Cited by 194
Dmitrieva-Posocco, O., Dzutsev, A., Posocco, D. F., Hou, V., Yuan, W., Thovarai, V., Mufazalov, I. A., Gunzer, M., Shilovskiy, I. P., Khaitov, M. R., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.015 · Cited by 188
Ding, L., Ren, J., Zhang, D., Li, Y., Huang, X., Hu, Q., Wang, H., Song, Y., Ni, Y., & Hou, Y. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy006 · Cited by 184
Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses
Mora, J., Schlemmer, A., Wittig, I., Richter, F., Putyrski, M., Frank, A.-C., Han, Y., Jung, M., Ernst, A., Weigert, A., et al. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw006 · Cited by 180
Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP
Fabbi, M., Carbotti, G., & Ferrini, S. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ru0714-360rr · Cited by 177
Wu, T.-C., Xu, K., Martinek, J., Young, R. R., Banchereau, R., George, J., Turner, J., Kim, K. I., Zurawski, S., Wang, X., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0413 · Cited by 165
Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Kocsis, J., Nemecek, R., Rogowski, W., Lesniewski-Kmak, K., Petruzelka, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30006-2 · Cited by 164
Castaño, Z., San Juan, B. P., Spiegel, A., Pant, A., DeCristo, M. J., Laszewski, T., Ubellacker, J. M., Janssen, S. R., Dongre, A., Reinhardt, F., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0173-5 · Cited by 162
IL-33 activates tumor stroma to promote intestinal polyposis
Maywald, R. L., Doerner, S. K., Pastorelli, L., Salvo, C. D., Benton, S. M., Dawson, E. P., Lanza, D. G., Berger, N. A., Markowitz, S. D., Lenz, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422445112 · Cited by 159
Rider, P., Carmi, Y., Voronov, E., & Apte, R. N. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.005 · Cited by 155
Chen, S.-F., Nieh, S., Jao, S., Wu, M.-Z., Liu, C., Chang, Y., & Lin, Y. (2013) · The Journal of Pathology · doi:10.1002/path.4226 · Cited by 153
Tjomsland, V., Spångéus, A., Välilä, J., Sandström, P., Borch, K., Druid, H., Falkmer, S. E., Falkmer, S., Messmer, D., & Larsson, M. (2011) · Neoplasia · doi:10.1593/neo.11332 · Cited by 141
Identification of a Novel Human Cytokine Gene in the Interleukin Gene Cluster on Chromosome 2q12-14
Bensen, J. T., Dawson, P. A., Mychaleckyj, J. C., & Bowden, D. W. (2001) · Journal of Interferon & Cytokine Research · doi:10.1089/107999001753289505 · Cited by 141
Voigt, C., May, P., Gottschlich, A., Markota, A., Wenk, D., Gerlach, I., Voigt, S., Stathopoulos, G. T., Arendt, K. A. M., Heise, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705165114 · Cited by 141
IL-18-producing Salmonella inhibit tumor growth
Loeffler, M. W., Le'Negrate, G., Krajewska, M., & Reed, J. C. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.48 · Cited by 135
Gao, K., Li, X., Zhang, L., Bai, L., Dong, W., Gao, K., Shi, G., Xia, X., Wu, L., & Zhang, L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.002 · Cited by 135
Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasis
Andersson, P., Yang, Y., Hosaka, K., Zhang, Y., Fischer, C., Braun, H., Liu, S., Yu, G., Liu, S., Beyaert, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122375 · Cited by 133
Boutet, M., Najm, A., Bart, G., Brion, R., Touchais, S., Trichet, V., Layrolle, P., Gabay, C., Palmer, G., Blanchard, F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210630 · Cited by 132
ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma
Jovanović, I., Radosavljevic, G. D., Mitrović, M., Lisnić, V. J., McKenzie, A. N. J., Arsenijević, N., Jonjić, S., & Lukić, M. L. (2011) · European Journal of Immunology · doi:10.1002/eji.201141417 · Cited by 131
Tarhini, A. A., Millward, M., Mainwaring, P. N., Kefford, R. F., Logan, T., Pavlick, A. C., Kathman, S. J., Laubscher, K. H., Dar, M. M., & Kirkwood, J. M. (2009) · Cancer · doi:10.1002/cncr.24100 · Cited by 127
The Role of IL-33/ST2 Pathway in Tumorigenesis
Larsen, K. M., Minaya, M. K., Vaish, V., & Peña, M. M. O. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092676 · Cited by 124
Wang, X., Zhao, X., Feng, C., Weinstein, A. M., Xia, R., Wen, W., Lv, Q., Zuo, S., Tang, P., Yang, X., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.014 · Cited by 123
Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells
Haabeth, O. A. W., Lorvik, K. B., Yagita∥, H., Bogen, B., & Corthay, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1039763 · Cited by 119
Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F., Viaud, S., Ryffel, B., Yagita∥, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3379 · Cited by 117
Uppendahl, L. D., Felices, M., Bendzick, L. E., Ryan, C., Kodal, B., Hinderlie, P., Boylan, K. L. M., Skubitz, A. P. N., Miller, J. S., & Geller, M. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.01.006 · Cited by 117
Kuan, E. L., & Ziegler, S. F. (2018) · Nature Immunology · doi:10.1038/s41590-018-0066-6 · Cited by 116
Oh, K., Lee, O.-Y., Park, Y., Seo, M. W., & Lee, D. (2016) · BMC Cancer · doi:10.1186/s12885-016-2746-7 · Cited by 110
Akimoto, M., Maruyama, R., Takamaru, H., Ochiya, T., & Takenaga, K. (2016) · Nature Communications · doi:10.1038/ncomms13589 · Cited by 110
Choi, I.-K., Lee, J.-S., Zhang, S.-N., Park, J. H., Lee, K.-M., Sonn, C. H., & Yun, C.-O. (2011) · Gene Therapy · doi:10.1038/gt.2011.37 · Cited by 109
Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells
Zhao, J.-J., Pan, Q., Pan, K., Weng, D., Wang, Q.-J., Li, X. H., Lv, L., Wang, D., Zheng, H.-X., Jiang, S.-S., et al. (2014) · Scientific Reports · doi:10.1038/srep05177 · Cited by 108
Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer
Dominguez, D., Ye, C., Geng, Z., Chen, S., Fan, J., Qin, L., Long, A., Wang, L., Zhang, Z., Zhang, Y., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501399 · Cited by 105
Watari, K., Shibata, T., Kawahara, A., Sata, K.-I., Nabeshima, H., Shinoda, A., Abe, H., Azuma, K., Murakami, Y., Izumi, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099568 · Cited by 104
Carrascal, M. T., Mendoza, L., Valcárcel, M., Salado, C., Egilegor, E., Tellería, N., Vidal‐Vanaclocha, F., & Dinarello, C. A. (2003) · PubMed · Cited by 102
Mosley, B., Dower, S., Gillis, S. A., & Cosman, D. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.13.4572 · Cited by 101
Biology of IL ‐38 and its role in disease
van de Veerdonk, F. L., de Graaf, D. M., Joosten, L. A. B., & Dinarello, C. A. (2017) · Immunological Reviews · doi:10.1111/imr.12612 · Cited by 98
Weinstein, A. M., Giraldo, N. A., Petitprez, F., Julié, C., Lacroix, L., Peschaud, F., Emile, J., Marisa, L., Fridman, W. H., Storkus, W. J., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2259-0 · Cited by 96
Kim, K.-E., Song, H., Kim, T. S., Yoon, D., Kim, C.-W., Bang, S. I., Hur, D. Y., Park, H., & Cho, D.-H. (2006) · Oncogene · doi:10.1038/sj.onc.1209926 · Cited by 95
Melisi, D., Niu, J., Chang, Z., Xia, Q., Peng, B., Ishiyama, S., Evans, D. B., & Chiao, P. J. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0201 · Cited by 95
Liu, S., Lee, J. S., Jie, C., Park, M. H., Iwakura, Y., Patel, Y. K., Soni, M., Reisman, D., & Chen, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2761 · Cited by 95
Regulatory Mechanisms of IL-33-ST2-Mediated Allergic Inflammation
Takatori, H., Makita, S., Ito, T. K., Matsuki, A., & Nakajima, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02004 · Cited by 95
Gao, W., Kumar, S., Lotze, M. T., Hanning, C. R., Robbins, P. D., & Gambotto, A. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.107 · Cited by 93
Weinstein, A. M., Chen, L., Brzana, E. A., Patil, P. R., Taylor, J. L., Fabian, K. P., Wallace, C. T., Jones, S. D., Watkins, S. C., Lu, B., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1322238 · Cited by 92
The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment
Wasmer, M.-H., & Krebs, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00682 · Cited by 87
Yang, Y., Cheon, S., Jung, M. K., Song, S. B., Kim, D., Kim, H. J., Park, H., Bang, S. I., & Cho, D. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.108 · Cited by 85
An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer
O’Donnell, C., Mahmoud, A., Keane, J. M., Murphy, C., White, D., Carey, S., O‘Riordain, M., Bennett, M., Brint, E. K., & Houston, A. M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.433 · Cited by 85
Self-citationIL-33 signaling fuels outgrowth and metastasis of human lung cancer
Wang, C., Chen, Z., Bu, X., Yang, H., Shan, S., Ren, T., & Song, W. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.081 · Cited by 80
León, X., Bothe-González, C., García, J., Parreño, M., Alcolea, S., Quer, M., Vila, L., & Camacho, M. (2015) · Oncotarget · doi:10.18632/oncotarget.6054 · Cited by 77
Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma
Tangkijvanich, P., Thong‐Ngam, D., Mahachai, V., Theamboonlers, A., & Poovorawan, Y. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i32.4345 · Cited by 76
Saranchova, I., Han, J. S., Huang, H., Fenninger, F., Choi, K. B., Munro, L., Pfeifer, C. G., Welch, I. D., Wyatt, A. W., Fazli, L., et al. (2016) · Scientific Reports · doi:10.1038/srep30555 · Cited by 74
Douvdevani, A., Huleihel, M., Zöller, M., Segal, S., & Apte, R. N. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510526 · Cited by 73
The enigmatic role of IL-38 in inflammatory diseases
Garraud, T., Harel, M., Boutet, M., Goff, B. L., & Blanchard, F. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.01.001 · Cited by 73
Lim, H. X., Hong, H.-J., Cho, D., & Kim, T. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401282 · Cited by 71
The Association of Serum IL-33 and sST2 with Breast Cancer
Yang, Z., Ling, D.-Y., Xie, Y., Wu, W., Li, J.-R., Jiang, J. F., Zheng, J.-L., Fan, Y., & Zhang, Y. (2015) · Disease Markers · doi:10.1155/2015/516895 · Cited by 68
IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2
Li, Y., Shi, J., Qi, S., Zhang, J., Peng, D., Chen, Z., Wang, G., Wang, Z., & Wang, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0839-7 · Cited by 68
Role for nuclear interleukin-37 in the suppression of innate immunity
Li, S., Amo‐Aparicio, J., Neff, C. P., Tengesdal, I. W., Azam, T., Palmer, B. E., López‐Vales, R., Bufler, P., & Dinarello, C. A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821111116 · Cited by 67
Tomimatsu, S., Ichikura, T., & Mochizuki, H. (2001) · Cancer · doi:10.1002/1097-0142(20010401)91:7<1272::aid-cncr1128>3.0.co;2-z · Cited by 63
Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10
Charbonneau, B., Block, M. S., Bamlet, W. R., Vierkant, R. A., Kalli, K. R., Fogarty, Z. C., Rider, D. N., Sellers, T. A., Tworoger, S. S., Poole, E., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1051 · Cited by 62
Akimoto, M., Hayashi, J.-I., Nakae, S., Saito, H., & Takenaga, K. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.418 · Cited by 61
Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia
Qin, L., Dominguez, D., Chen, S., Fan, J., Long, A., Zhang, M., Fang, D., Zhang, Y., Kuzel, T. M., & Zhang, B. (2016) · Oncotarget · doi:10.18632/oncotarget.11179 · Cited by 61
Dagenais, M., Dupaul-Chicoine, J., Douglas, T., Champagne, C., Morizot, A., & Saleh, M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1287247 · Cited by 60
Xu, D., Matsuo, Y., Ma, J., Koide, S., Ochi, N., Yasuda, A., Funahashi, H., Okada, Y., & Takeyama, H. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21530 · Cited by 57
Circulating IL-33 level is associated with the progression of lung cancer
Kim, M., Kim, E., Heo, J.-S., Bae, D.-J., Lee, J.-U. W., Lee, T.-H., Lee, H. J., Chang, H. S., Park, J., Jang, A., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.011 · Cited by 56
IL-37 mediates the antitumor activity in renal cell carcinoma
Jiang, Y., Wang, Y., Liang, L., Gao, Y., Chen, J., Sun, Y. J., Cheng, Y., & Xu, Y. (2015) · Medical Oncology · doi:10.1007/s12032-015-0695-7 · Cited by 54
Expression of ADAM33 Is a Novel Regulatory Mechanism in IL-18-Secreted Process in Gastric Cancer
Kim, K.-E., Song, H., Hahm, C., Yoon, S. Y., Park, S., Lee, H., Hur, D. Y., Kim, T. S., Kim, C.-H., Bang, S. I., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801695 · Cited by 53
Voronov, E., Weinstein, Y., Benharroch, D., Cagnano, E., Ofir, R., Dobkin, M., White, R. M., Zöller, M., Barak, V., Segal, S., et al. (1999) · PubMed · Cited by 51
Jiang, M., Wang, Y., Zhang, H., Ji, Y., Zhao, P., Sun, R., & Zhang, C. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12628 · Cited by 50
Takada, K., Okamoto, T., Tominaga, M., Teraishi, K., Akamine, T., Takamori, S., Katsura, M., Toyokawa, G., Shoji, F., Okamoto, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181598 · Cited by 48
Luo, C., Shu, Y., Luo, J., Liu, D., Huang, D.-S., Han, Y., Chen, C., Li, Y., Zou, J.-M., Qin, J., et al. (2017) · Oncogene · doi:10.1038/onc.2016.444 · Cited by 47
Kurzrock, R., Hickish, T., Wyrwicz, L. S., Saunders, M. P., Wu, Q., Stecher, M., Mohanty, P., Dinarello, C. A., & Simard, J. J. L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1551651 · Cited by 47
IL-37 Is a Novel Proangiogenic Factor of Developmental and Pathological Angiogenesis
Yang, T., Lin, Q., Zhao, M., Hu, Y., Yu, Y., Jin, J., Zhou, H., Hu, X., Wei, R., Zhang, X., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306543 · Cited by 46
Millar, N. L., O’Donnell, C., McInnes, I. B., & Brint, E. K. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.007 · Cited by 45
Self-citationSuppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases
Sullivan, G. P., Henry, C. M., Clancy, D. M., Mametnabiev, T. E., Belotcerkovskaya, E., Davidovich, P. B., Sura‐Trueba, S., Garabadzhiu, A. V., & Martin, S. J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0385-4 · Cited by 45
Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation
Li, Y., Zhao, M., Guo, C., Chu, H., Li, W., Chen, X.-L., Wang, X., Li, Y., Jia, Y., Koussatidjoa, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.405 · Cited by 42
Robertson, M. J., Kline, J. P., Struemper, H., Koch, K. M., Bauman, J. W., Gardner, O., Murray, S. C., Germaschewski, F., Weisenbach, J., Jonak, Z., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829d7e2e · Cited by 41
Liu, R., Tang, C., Shen, A., Luo, H., Wei, X., Zheng, D., Sun, C., Li, Z., Zhu, D., Li, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13196 · Cited by 41
Elkabets, M., Krelin, Y., Dotan, S., Cerwenka, A., Porgador, A., Lichtenstein, R. G., White, M. R., Zöller, M., Iwakura, Y., Dinarello, C. A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803916 · Cited by 35
Singer, C. F., Hudelist, G., Gschwantler‐Kaulich, D., et al. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00695.x · Cited by 35
Chen, Y., Sun, J., Huang, Y., Liu, Y., Liang, L., Yang, D., Lu, B., & Li, S. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.09.005 · Cited by 35
Epidermal growth factor is a critical regulator of the cytokine IL‐33 in intestinal epithelial cells
Islam, M. S., Horiguchi, K., Iino, S., Kaji, N., Mikawa, S., Hori, M., & Ozaki, H. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13535 · Cited by 33
Interleukin-33 enhanced the migration and invasiveness of human lung cancer cells
Yang, Z., Gao, X., Wang, J., Xu, L., Zheng, Y., & Xu, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s155905 · Cited by 31
Valcárcel, M., Carrascal, T., Crende, O., & Vidal‐Vanaclocha, F. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.342 · Cited by 28
Zhang, Y., Xiao, Y., Lin, D., Lei, L., Hu, B., Cao, F., Mei, Y., Wu, D., & Liu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.14934 · Cited by 28
Dinarello, C. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2225 · Cited by 26
Decreased expression of interleukin-36α predicts poor prognosis in colorectal cancer patients.
Wang, Z., Cong, Z., Luo, Y., Mu, Y., Qin, S., Zhong, M., & Chen, J. (2014) · Europe PMC (PubMed Central) · Cited by 23
Wang, L., Li, H., Liang, F., Yi, H., Jiang, S., & Xiao, L. (2014) · Medical Oncology · doi:10.1007/s12032-014-0143-0 · Cited by 19
A Role for Interleukin-1 Alpha in the 1,25 Dihydroxyvitamin D3 Response in Mammary Epithelial Cells
Maund, S. L., Shi, L., & Cramer, S. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081367 · Cited by 18
Cited by
Macrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,229
Emerging connectivity of programmed cell death pathways and its physiological implications
Bedoui, S., Herold, M. J., & Strasser, A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0270-8 · Cited by 979
Chemotherapy: a double-edged sword in cancer treatment
Behranvand, N., Nasri, F., Zolfaghari Emameh, R., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 397
The Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332
Programmed Cell Death Tunes Tumor Immunity
Liu, J., Hong, M., Li, Y., Chen, D., Wu, Y., & Hu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847345 · Cited by 316
Metadata
- Authors
- Baker, K. J., Houston, A., & Brint, E.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-06-07
- Volume
- 10
- Pages
- 1197-1197
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2945398765
- Cited by
- 284
- References
- 136
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.